medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Number 2

<< Back Next >>

Rev Invest Clin 2005; 57 (2)

Hematopoietic stem-cell transplantation in multiple myeloma

Vela-Ojeda J, García REMA

Language: Spanish
References: 50
Page: 305-313
PDF size: 75.99 Kb.


ABSTRACT

Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients per year in the United States. For over four decades, the standard treatment for MM has been a regimen of melphalan combined with prednisone. Using this treatment modality, complete responses are rare, and 50% of patients have had disease that was resistant to chemotherapy. Attempts have been made to improve the outcome of MM by administering combinations of I.V. polichemotherapy, but these treatments are equivalent in terms of overall survival. High-dose therapy with peripheral blood stem cell support can be applied safely in these patients and achieves significantly higher complete remission rates as well as better event-free survival and overall survival. However, neither tumor-cell purging, positive selection, intensification of conditioning with additional chemotherapeutic agents, nor total body irradiation have been shown to improve outcome. The role of tandem transplantation with high-dose melphalan seems to be a good selection of treatment in hospitals having all resources. Future research will include the combination of the best remission-induction regimen with tandem transplants and maintenance treatments (thalidomide, idiotype or dendritic cell vaccination) that will sustain complete remission. Development of non-myeloablative allogeneic transplantation in order to exploit the graft-versus myeloma effect provides an alternative for patients who have a compatible donor. Combining all of these modalities with the new drugs developed few years ago (thalidomide, bortezomib, revlimid), we hope that MM will become a manageable chronic disease and perhaps a curable disease at least for 30% to 40% of the patients.


REFERENCES

  1. Bergsagel DE, Sprage CC, Austin C, Griffith KM. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-phenylalanine mustard (NSC-8806). Cancer Chemother Rep 1962; 21: 87.

  2. Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-42.

  3. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983; 2: 822-4.

  4. Tricot G, Alberts DS, Johnson C. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947-52.

  5. Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J. Intermediate doses of melphalan and dexamethasone are better than vincristine, adryamicin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol 2002; 81: 362-7.

  6. Jagannath S, Vesole DH, Tricot G. Hemopoietic stem cell transplants for multiple myeloma. Oncology 1994; 8: 89-103.

  7. Moreau P, Milpied N, Mahe B. Melphalan 200 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003-6.

  8. Attal M, Harousseau JL, Stoppa AM. Prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 355: 91-7.

  9. Attal M, Harousseau JL. Randomized trial experience of the Intergroup Francophone du Myelome. Semin Hematol 2001; 38: 226-30.

  10. Child JA, Morgan GJ, Davies FE. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.

  11. Palumbo A, Bringhen S, Petrucci MT. A prospective randomized trial of intermediate dose melphalan (100 mg/m2) vs. oral melphalan/prednisone. Blood 2003; 102: 984a.

  12. Fermand JP, Ravaud P, Kateshian S. High-dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation vs. conventional therapy in multiple myeloma (MM): results of a randomized trial in 190 patients 55-65 years of age. Blood 1999; 94: 396a.

  13. Bladé J, Sureda A, Ribera JM. High dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: definitive results from PETHEMA after a median follow-up of 66 months. Blood 2003; 102: 42a.

  14. Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G, Carver JR, Kyle RA, McCarthy PL. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review. Biol Blood Marrow Transplant 2003; 9: 4-37.

  15. Fermand JP, Ravaud P, Chevret S. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-6.

  16. Hawkins T, Horvat N, Rawling C. An incremental response to high-dose therapy in multiple myeloma. Bone Marrow Transplant 1996; 17: 929-35.

  17. Harousseau JL, Attal M, Divine M. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant 1995; 15: 963-9.

  18. Vescio RA, Han EJ, Schiller GJ. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autograft. Bone Marrow Transplant 1996; 18: 103-10.

  19. Alegre A, Tomas JF, Martinez-Chamorro C. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophpsphamide plus GM-CSF vs. G-CSF alone. Bone Marrow Transplant 1997; 20: 211-17.

  20. Galimberti S, Morabito F, Guerrini F. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003; 120: 405-12.

  21. Fallon P, Gentry T, Balber AE. Mobilized peripheral blood SSCIoALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol 2003; 122: 99-108.

  22. Moreau P, Facon T, Attal M, Hulin C, Michalet M, Maloisel F, Sotto JJ. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731-5.

  23. Cogle CR, Moreb JS, Leather HL. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Hematol 2003; 73: 169-75.

  24. Harousseau JL, Milpied N, Laporte JP. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827-33.

  25. Barlogie B, Jagannath S, Desikan KR. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.

  26. Barlogie B, Jagannath S, Vesole DH. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-93.

  27. Attal M, Harousseau JL, Facon T. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.

  28. Singhal S, Metha J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.

  29. Barlogie B, Zangari M, Spencer T. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38: 250-9.

  30. Gahrton G, Svensson H, Björkstrand B. Syngeneic transplantation in multiple myeloma: a case matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999; 24: 741-5.

  31. Bensinger W, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38: 242-9.

  32. Gahrton G, Svensson H, Cavo M. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation Centres. Br J Haematol 2001; 113: 209-16.

  33. Lokhorst HM, Segreen CM, Verdonk LE. Partially T cell depleted allogeneic stem-cell transplantation for first line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728-33.

  34. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft versus myeloma effect: proof of principle. Blood 1996; 87: 1196-8.

  35. Lokhorst HM, Schattemberg A, Cornelissen JJ, Van Oers MH, Fibbe W, Russel I, Donk NW, Verdonck LF. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long term outcome. J Clin Oncol 2000; 18: 3031-7.

  36. Salama M, Nevill T, Marcellus D. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-84.

  37. Einsele H, Schafer HJ, Hebart H. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced intensity conditioning. Br J Haematol 2003; 121: 411-18.

  38. Badros A, Barlogie B, Siegel E. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol 2002; 20: 1295-1303.

  39. Kroger N, Schwerdtfeger R, Kiehl M. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-60.

  40. Maloney DG, Molina AJ, Sahebi F. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-54.

  41. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.

  42. Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511-15.

  43. Treon SP, Pilarski LM, Belch AR. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72-81.

  44. Kumar S, Kimlinger TK, Lust JA. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003; 102: 1075-7.

  45. Gasparetto C, Rooney R, Rooney B. Multiple myeloma cells express CD52 and are sensitive to treatment with Campath-1H. Blood 2002; 3210a.

  46. Massaia M, Borrione P, Battaglio S. Idiotype vaccination in human myeloma: generation of tumor-specific immune response after high-dose chemotherapy. Blood 1999; 94: 673-83.

  47. Kim SB, Baskar S, Kwak LW. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leuk Lymphoma 2003; 44: 1201-8.

  48. Titzer S, Christensen O, Manzke O. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000; 108: 805-16.

  49. Richardson PG, Schlossman RJ, Weller E. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-7.

  50. Mitsiades N, Mitsiades CS, Richardson PG. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80.




2020     |     www.medigraphic.com